Advanced Refractory Left Ventricular Heart Failure Clinical Trial
Official title:
Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol
The objective of the study is to evaluate the safety and effectiveness of the HM3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
The HM3 LVAS is intended to provide hemodynamic support in patients with advanced, refractory left ventricular heart failure; either for short term support, such as a bridge to cardiac transplantation (BTT) or myocardial recovery, or as long term support, such as destination therapy (DT). The HM3 is intended for use inside or outside the hospital. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04548128 -
Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical SWIFT HM3 PMS
|
||
Completed |
NCT03022461 -
HeartMate 3 CE Mark Study Long Term Follow-up
|
||
Completed |
NCT02170363 -
HeartMate 3™ CE Mark Clinical Investigation Plan
|
N/A | |
Completed |
NCT03982979 -
MOMENTUM 3 Pivotal Cohort Extended Follow-up PAS
|
||
Completed |
NCT02892955 -
MOMENTUM 3 Continued Access Protocol
|
N/A |